Annovis Bio Names Hui Liu Director of Biostatistics for Phase 3 Alzheimer’s Trial
Annovis Bio appoints Hui Liu as Director of Biostatistics for Phase 3 Alzheimer’s trial, reinforcing data integrity and regulatory strategies for transformative neurodegenerative therapies.
This news highlights the crucial role of Hui Liu in advancing Annovis Bio's mission to address neurodegeneration, potentially leading to groundbreaking treatments for patients suffering from Alzheimer's and Parkinson's diseases.